Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: A preliminary report

Transplantation

Volumn 68, Issue 1, 1999, Pages 155-157

  Papatheodoridis, George V ^a   O'beirne, James ^a   Mistry, Pramod ^a   Davidson, Brian ^a   Rolles, Keith ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; ENZYME ACTIVITY; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY INJURY; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033565555     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199907150-00029     Document Type: Article

References (10)

1. Porayko MK, Textor SC, Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994; 69: 105.
2. Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19: 925.
3. Chan C-Y, DasGupta K, Baker AL. Cyclosporin A: drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996; 24: 1085.
4. Lipsky JL. Mycophenolate mofetil. Lancet 1996; 348: 1357.
5. Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate. Transplantation 1997; 64: 1755.
6. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65: 180.
7. Ahmed E, Perkins JD, Rakela J, Krom RAF. Conversion from standard cyclosporine to low-dose cyclosporine in liver transplant recipients: effect on nephrotoxicity and hypertension beyond one year. Transplant Proc 1989; 21: 2238.
8. Herrero JI, Guiroga J, Sangro B, et al. Conversion from cyclosporine A to mycophenolate mofetil in liver transplant recipients with renal function impairment. Transplantation 1998; 65: S51.
9. Jain A, Fung J, Hamad I, Zuckerman S, Starzl TE, Venkataramanan DR. Use of mycophenolate mofetil for tacrolimus related chronic nephrotoxicity in liver transplant recipients. Hepatology 1997; 26 (Suppl.): 235A.
10. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil: an alternative maintenance immunosuppressant in liver transplantation, which improves renal dysfunction. Hepatology 1998; 28 (Suppl.): 267A.